Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internatio…
$83.82+1.04%
报价 2026-11-13
市值
$34.06B
EV
$57.96B
PE (TTM)
18.9x
预期 PE (FY2026)
13.3x
52 周区间距高点 -36.1%
$69.10$131.10
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-13未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.0x | 6.63 → 6.31(1.0x) | 13.3 |
| FY+32028-12 | 1.0x | 6.63 → 6.73(1.0x) | 12.5 |
毛利率 70% · TTM 收入 $9508M · 基数 EPS 6.63(调整后)
电话会信号
辅助标签Q3 20262026-11-05
无标签
指引 有升有降
信心 2
分析师 3
“We will not be assuming improvements in the macro environment or pet owner spending trends, and we expect the competitive dynamics to remain a factor.”
蓝色标签在暴涨研究中略有区分度;悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ZTSZoetis Inc. | $34.06B | +1.0% | -1.6% | 70.5% | 18.9x | 14.2x | 15.0x | |
| REGNRegeneron Pharmaceuticals, Inc. | $98.82B | +0.5% | +31.5% | 85.8% | 19.8x | 15.1x | 26.6x | |
| ELVElevance Health Inc. | $92.84B | -0.0% | +0.7% | 25.6% | 11.3x | 9.1x | 14.3x | |
| CICigna Corporation | $78.26B | +0.2% | +5.9% | 9.5% | 11.7x | 7.8x | 9.5x | Cheap |
| CORCencora, Inc. | $68.51B | +3.0% | +4.6% | 4.3% | 23.2x | 13.6x | 15.1x | |
| TAKTakeda Pharmaceutical Company Limited | $68.13B | +1.5% | – | 59.5% | 79.2x | 9.8x | – | |
| ARGXargenx SE | $60.37B | -2.2% | – | 89.9% | 38.2x | 39.0x | 58.5x | |
| BDXBecton, Dickinson and Company | $59.39B | +1.1% | +2.4% | 45.8% | 25.3x | 14.7x | 21.1x | |
| IDXXIDEXX Laboratories, Inc. | $55.48B | +0.9% | +10.8% | 62.9% | 47.6x | 33.7x | 42.8x | |
| 同行中位数 | – | – | +5.3% | 52.6% | 24.3x | 14.2x | 21.1x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。